

CURRICULUM VITAE

Alan Kooi Davis, Ph.D.

Date: July 2023

DEMOGRAPHIC AND PERSONAL INFORMATION

Academic Appointments

- 2019 - 2023 Assistant Professor
College of Social Work
The Ohio State University
Columbus, OH
- 2019 - Present Adjunct Assistant Professor
Center for Psychedelic and Consciousness Research
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University
Baltimore, MD
- 2021 – Present Assistant Professor
Department of Psychiatry
College of Medicine
The Ohio State University
- 2023 - Present Associate Professor with Tenure
College of Social Work
The Ohio State University
Columbus, OH

Administrative Appointments

- 2022 – Present Director
Center for Psychedelic Drug Research and Education
College of Social Work
The Ohio State University
Columbus, OH

Contact Information

1947 College Rd. Columbus, OH 43210
Email: davis.5996@osu.edu / adavi157@jhmi.edu
Websites: [Ohio State](#) / [Research Gate](#) / [Johns Hopkins](#) / [Source Research Foundation](#)

Education and Training

- 2008 – 2010 Bachelor of Liberal Studies, Human Services - Summa Cum Laude
Wingate University - Wingate, NC
- 2010 – 2012 Master of Arts, Clinical Psychology
Bowling Green State University - Bowling Green, OH
- 2012 – 2016 Doctor of Philosophy, Clinical Psychology (APA Accredited)
Bowling Green State University - Bowling Green, OH
- 2015 – 2016 Predoctoral Psychology Internship in Clinical Psychology (APA Accredited)
VA Maryland Healthcare System
& University of Maryland School of Medicine Consortium - Baltimore, MD

- 2016 – 2017 NIAAA T32 Postdoctoral Research Fellow
Addiction Center, Department of Psychiatry
University of Michigan - Ann Arbor, MI
- 2017 – 2017 Graduate Certificate in Psychedelic-assisted Therapy and Research
California Institute of Integral Studies - San Francisco, CA
- 2017 – 2019 NIDA T32 Postdoctoral Research Fellow
Behavioral Pharmacology Research Unit, Department of Psychiatry
Johns Hopkins University School of Medicine - Baltimore, MD

Professional Experience

- 2005 – 2009 Paraprofessional, Addiction Counselor, Director of Treatment Services
McLeod Addictive Disease Center - Charlotte, NC
- 2017 – 2018 Clinical Trial Assessment Rater for MDMA-assisted Therapy Studies
Multidisciplinary Association of Psychedelic Studies
MAPS Public Benefit Corporation – Santa Cruz, CA
- 2023 – Present Member, Comprehensive Cancer Center
The Ohio State University Medical Center – Columbus, OH

Interviews/Media and Presentations

- Radio/Podcasts: [Mind&Matter](#) / [NPR-Cincinnati](#) / [NPR 2021](#) / [WSJ](#) / [JAMA](#) / [NPR 2020](#) / [WPR](#) / [WBUR](#) / [Research Matters](#) / [Man Talk](#)
- Print/Online: [Columbus Monthly](#) / [The New Yorker](#) / [New York Times](#) / [Teen Vogue](#) / [Yahoo News](#) / [Time](#) / [CNN](#) / [NBC](#) / [Elemental](#) / [Popular Science](#) / [Newsweek](#) / [Vogue](#) / [Men's Journal](#) / [Vox](#) / [Daily Mail](#) / [Hopkins Magazine](#) / [Big Think](#) / [Vice](#) / [Psychology Today](#) / [Science Daily](#)
- Audio/Video Presentations: [Breaking Convention 2023](#) / [Fox8](#) / [Spectrum News](#) / [NBC-Cleveland](#) / [Mt Sinai](#) / [CBS](#) / [Ohio State University](#) / [Yale](#) / [University of Michigan](#) / [Horizons-NYC](#) / [Psilocybin Summit](#)
- Ohio State University Media: [March 2021](#) / [December 2020](#) / [OSU Video News](#)

RESEARCH ACTIVITIES

Research Focus

- 1) Exploring the acute and persisting effects of psychoactive substances
- 2) Understanding determinants of problematic patterns of substance use and associated harms
- 3) Investigating the individual and systemic barriers to addiction treatment retention and successful outcomes
- 4) Examining novel psychological and pharmacological interventions.

Editorial Board Appointments

- 2013 – 2015 Editorial Advisory Board (Member)
The Journal of NAADAC: Advances in Addiction & Recovery
- 2019 – 2020 Guest Editor (with Jason Luoma, Rosalind Watts, and Lance McCracken)
Special Section on Psychedelic Science
Journal of Contextual Behavioral Science
- 2020 – Present Associate Editor
Journal of Psychedelic Studies

2022 – Present Editorial Board
Journal of Psychopharmacology

2022 – 2023 Guest Editor: Psychedemia Special Issue
Journal of Psychedelic Studies

Ad-hoc reviewer

Journal of the American Medical Association (JAMA); European Journal of Trauma and Dissociation; Addiction; Human Psychopharmacology: Clinical and Experimental; Drug and Alcohol Dependence; Journal of Psychopharmacology; Chronic Stress; Psychopharmacology; Journal of Contextual Behavioral Science; Drug Science, Policy, and Law; Addictive Behaviors; Psychology of Consciousness: Research, Theory, and Practice; Psychology of Addictive Behaviors; PLOS One; Complimentary Therapies in Medicine; American Journal of Drug and Alcohol Abuse; Journal of Psychoactive Drugs; Addiction Research and Theory; Substance Abuse; Journal of Studies on Alcohol and Drugs; Journal of Psychedelic Studies; Journal of Alcohol and Alcoholism; Social Psychiatry and Psychiatric Epidemiology; Psychological Medicine, Clinical Psychologist; Scientific Reports; American Journal of Drug and Alcohol Abuse; Cancer; Journal of Pain and Symptom Management

Publications (94)

(GS metrics: h-index = 28, i10 = 53, citations = 3662)

underlined text indicates mentee/student status at time of publication

Book Chapters

1. Lancelotta, R. & **Davis, A K.** (2021). Therapeutic potential of fast-acting tryptamines. In C. Grob and J. Grigsby (Eds.), *Handbook of Medical Hallucinogens* (pp. 215-226). New York, NY: Guilford Publications
2. Agin-Liebes, G. & **Davis, A. K.** (2022). Psilocybin for the treatment of depression. In F. S. Barrett & Preller, K. (Eds.), *Current Topics in Behavioral Neurosciences: Disruptive Psychopharmacology* (pp. 125-140). New York, NY: Springer Nature, Switzerland

Editorials

1. Luoma, J. B., **Davis, A. K.**, Watts, R., & McCracken, L. M. (2020). Integrating contextual behavioral science with research on psychedelic assisted therapy: Introduction to the special section. *Journal of Contextual Behavioral Science*, 15, 207-209.

Journal Articles

1. Carels, R.A., Domoff, S., Burmeister, J., Koball, A., Hinman, N., **Davis, A.K.** ... Hoffman, D. (2013). Examining perceived stereotype threat among overweight/obese adults using a Multi-Threat Framework. *Obesity Facts*, 6, 258-268. DOI: 10.1159/000352029
2. **Davis, A.K.** & Rosenberg, H. (2013). Acceptance of non-abstinence goals by addiction professionals in the United States. *Psychology of Addictive Behaviors*, 27, 1102-1109. DOI: 10.1037/a0030563
3. Hoffmann, E., **Davis, A.K.**, Ashrafioun, L., Kraus, S., Rosenberg, H., Kryszak, E. ... Jesse, S. (2013). Evaluation of the criterion and predictive validity of the Alcohol Reduction Scale-Current Confidence (ARS-CC) in a natural drinking environment. *Addictive Behaviors*, 38, 1940-1943. DOI: 10.1016/j.addbeh.2012.12.021
4. Rosenberg, H. & **Davis, A.K.** (2014) Differences in the acceptability of non-abstinence goals by type of drug among American substance abuse clinicians. *Journal of Substance Abuse Treatment*, 46, 214-218. DOI: 10.1016/j.jsat.2013.07.005
5. **Davis, A.K.** & Rosenberg, H. (2014). The prevalence, intensity, and assessment of craving for MDMA/ecstasy in recreational users. *Journal of Psychoactive Drugs*, 46, 154-161. DOI: 10.1080/02791072.2014.901586

6. **Davis, A.K.**, Leith, J., Osborn, L.A., Rosenberg, H., Ashrafioun, L., Hawley, A., ... Baik, K. (2014). Development and evaluation of the Marijuana Reduction Strategy Self-efficacy Scale. *Psychology of Addictive Behaviors*, 28, 575-579. DOI:10.1037/a0036665
7. **Davis, A.K.**, Osborn, L.A., Rosenberg, H., Cross, N., Lauritsen, K., Ashrafioun, L. ... Leith, J. (2014). Psychometric evaluation of the Marijuana Reduction Strategy Self-Efficacy Scale with a sample of young recreational marijuana users. *Addictive Behaviors*, 39, 1750-1754. DOI: 10.1016/j.addbeh.2014.07.005
8. **Davis, A.K.** & Rosenberg, H. (2015). Application of the Passionate Attachment model to recreational use of MDMA/ecstasy. *Journal of Psychoactive Drugs*, 47, 24-29. DOI: 10.1080/02791072.2014.973125
9. Osborn, L.A., Lauritsen, K., Cross, N., **Davis, A.K.**, Rosenberg, H., Bonadio, F., & Lang, B. (2015). Self-medication of somatic and psychiatric conditions using botanical marijuana. *Journal of Psychoactive Drugs*, 47, 345-350. DOI: 10.1080/02791072.2015.1096433
10. **Davis, A.K.** & Lauritsen, K. (2016). Acceptability of non-abstinence outcome goals among students enrolled in addiction studies programs across the United States. *Substance Abuse*, 37, 204-208. DOI: 10.1080/08897077.2015.1015702
11. Bradbury, S., **Davis, A.K.**, Leith, J., Hinman, N., Ashrafioun, L., Burmiester, J., & Dworsky, D. (2016). Attitudes and beliefs about the acceptability and justness of peer victimization of homosexual university students. *Journal of Homosexuality*, 63, 808-820. DOI: 10.1080/00918369.2015.1112581
12. **Davis, A. K.** & Rosenberg, H. (2016). Using the Theory of Planned Behavior to predict implementation of harm reduction strategies by MDMA/ecstasy users. *Psychology of Addictive Behaviors*, 30, 500-508. DOI: 10.1037/adb0000167
13. **Davis, A.K.**, Bonar, E.E., Ilgen, M., Walton, M., Perron, B., & Chermack, S., (2016). Factors Associated with Having a Medical Marijuana Card Among Veterans with Recent Substance Use in VA Outpatient Treatment. *Addictive Behaviors*, 63, 132-136. DOI:10.1016/j.addbeh.2016.07.006
14. Ashrafioun, L., Bonadio, F. A., Baik, K.D., Bradbury, S. L., Carhart, V. L., Cross, N. A., **Davis, A. K.**, ..., & Zaturenskaya, M. (2016). Patterns of use, acute subjective effects, and motivations for using synthetic cathinones ("bath salts") in recreational users. *Journal of Psychoactive Drugs*, 48, 336-343. DOI: 0.1080/02791072.2016.1229875
15. **Davis, A. K.** (2017). The Dualistic Model of Passion applied to recreational marijuana consumption. *Addiction Research and Theory*, 25, 188-194. DOI: 10.1080/16066359.2016.1242722
16. Lang, B., Rosenberg, H., Lauritsen, K. J., **Davis, A. K.**, & Cross, N. (2017). Psychometric evaluation of the Work Acceptance and Action Questionnaire-Student Form. *Journal of College Student Development*, 58, 1256-1260. DOI: 10.1353/csd.2017.0097
17. **Davis, A. K.** and Rosenberg, H. (2017). Specific harm reduction strategies used by MDMA/ecstasy users in the United States and the United Kingdom. *Drug Science, Policy, and Law*, 3, 1-8. DOI: 10.1177/2050324517711069
18. **Davis, A.K.**, Bonar, E.E., Goldstick J., Walton, M., Winters, J., & Chermack, S. (2017). Binge drinking and non-partner violence is associated with recent gambling among Veterans in VA outpatient mental health treatment. *Addictive Behaviors*, 74, 27-32. DOI: 10.1016/j.addbeh.2017.05.022
19. **Davis, A.K.**, Rosenberg, H., & Rosansky, J. (2017). American counselors' acceptance of non-abstinence outcome goals for clients diagnosed with co-occurring substance use and other psychiatric disorders. *Journal of Substance Abuse Treatment*, 82, 29-33. DOI: 10.1016/j.jsat.2017.08.006

20. **Davis, A.K.**, Barsuglia, J., Windam-Herman, M., Lynch, M. & Polanco, M. (2017). Effectiveness of Ibogaine-assisted treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. *Journal of Psychedelic Studies*, *1*, 65-73. DOI: 10.1556/2054.01.2017.009
21. **Davis, A.K.**, Lin, A., Ilgen, M. A., & Bohnert, K. (2018). Recent Cannabis Use among Veterans in the United States: Results from a National Sample. *Addictive Behaviors*, *76*, 223-228. DOI: 10.1016/j.addbeh.2017.08.010
22. **Davis, A.K.**, Walton, M., Bohnert, K. M., Bourque, C., & Ilgen, M. (2018). Factors associated with alcohol consumption among medical cannabis patients with chronic pain. *Addictive Behaviors*, *77*, 166-171. DOI: 10.1016/j.addbeh.2017.10.007
23. **Davis, A.K.**, Arterberry, B., Bonar, E.E., Bohnert, K.M., & Walton, M.A. (2018). Why do young people consume marijuana? Extending motivational theory via the dualistic model of passion. *Translational Issues in Psychological Science*, *4*, 54-64. DOI: 10.1037/adb0000354
24. Bonar, E. E., Arterberry, B. J., **Davis, A. K.**, Cunningham, R. C., Blow, F. C., Collins, L., & Walton, M. A. (2018). Prevalence and Motives for Drugged Driving among Emerging Adults Presenting to an Emergency Department. *Addictive Behaviors*, *78*, 80-84. DOI: 10.1016/j.addbeh.2017.11.002
25. **Davis, A. K.**, Nickelsen, T., Zucker, R. A., Bonar, E. E., & Walton, M. A. (2018). Acceptability of non-abstinent treatment outcome goals among addiction treatment providers in Ukraine. *Psychology of Addictive Behaviors*, *32*, 485-495. DOI: 10.1037/adb0000354
26. **Davis, A.K.**, Barsuglia, J. P., Lancelotta, R., Grant, R., & Renn, E. (2018). 5-Methoxy-Dimethyltryptamine: Benefits, consequences, patterns of use, motives for consumption, and acute subjective effects. *Journal of Psychopharmacology*, *32*, 779-792. DOI: 10.1177/0269881118769063
27. **Davis, A. K.**, Arterberry, B. J., Bonar, E. E., Chermack, S. T., Cunningham, R. M., Blow, F., & Walton, M. A. (2018). Predictors of positive treatment response among youth receiving a brief alcohol intervention in the emergency department. *Drug and Alcohol Dependence*, *188*, 102-108. DOI: 10.1016/j.drugalcdep.2018.03.044
28. **Davis, A.K.**, Renn, E., Windham-Herman, M., Polanco, M. & Barsuglia, J. (2018). A mixed method analysis of persisting effects associated with positive outcomes following Ibogaine detoxification. *Journal of Psychoactive Drugs*, *online ahead of print*, 1-11. DOI: 10.1080/02791072.2018.1487607
29. Goldstick, J., Bohnert, K., **Davis, A.K.**, Bonar, E. E., Carter, P., Walton, M.A., & Cunningham, R. (2018). Dual trajectories of depression/anxiety symptoms and alcohol use, and their implications for violence outcomes among drug-using urban youth. *Alcohol and Alcoholism*, *53*, 659-666. DOI: 10.1093/alcalc/agy036
30. Morris, D. H., **Davis, A. K.**, Lauritsen, K. J., Rieth, C. M., Winters, J. M., & Chermack, S. T. (2018). Substance use consequences, mental health problems, and readiness to change among Veterans seeking substance use treatment. *Journal of Substance Abuse Treatment*, *94*, 113-121. DOI: 10.1016/j.jsat.2018.08.005
31. Barsuglia, J., **Davis, A. K.**, Palmer, R., Lancelotta, R., Windham-Herman, A-M., Peterson, K., Polanco, M., Grant, R., & Griffiths, R. R. (2018). Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. *Frontiers in Psychology*, *9*, 1-6. DOI: 10.3389/fpsyg.2018.02459
32. Sexton, M. B., **Davis, A. K.**, Buchholz, K., Winters, J., Rauch, S., Yzquibell, M., Bonar, E. E., Friday, S., & Chermack, S. T. (2019). Veterans with recent substance use and aggression: PTSD, substance use, and social network behaviors. *Psychological Trauma: Theory, Research, Practice, and Policy*, *11*, 424-433. DOI: 10.1037/tra0000367
33. **Davis, A. K.**, So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R. (2019). 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) used in a naturalistic setting is associated with unintended improvements in depression and anxiety. *The American Journal of Drug and Alcohol Abuse*. DOI: 10.1080/00952990.2018.1545024.

34. Bonar, E. E., Goldstick, J., Cunningham, R. C., Fernandez, A., **Davis, A. K.**, Ilgen, M., & Walton, M. A. (2019). Individual and social factors related to trajectories of blackouts among underage drinkers in the emergency department. *Alcohol and Alcoholism*, *54*, 370-377. DOI: 10.1093/alcalc/agy087
35. Griffiths, R. R., Hurwitz, E., **Davis, A. K.**, Johnson, M. W., & Jesse, R. (2019). Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. *PLOS One*, *14*, e0214377. DOI: 10.1371/journal.pone.0214377
36. Arterberry, B. J., **Davis, A. K.**, Bonar, E. E., Walton, M. A., & Blow, F. C. (2019). Predictors of empirically-derived substance use patterns of sexual minority groups presenting to an urban emergency department. *Addictive Behaviors*, *96*, 76-81. DOI: 10.1016/j.addbeh.2019.04.021
37. Garcia-Romeu, A., **Davis, A. K.**, Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. *Journal of Psychopharmacology*, *33*, 1088-1101. DOI: 10.1177/0269881119845793
38. **Davis, A. K.** & Arterberry, B. J. (2019). Passion for marijuana use mediates the relations between refusal self-efficacy and use/consequences. *Journal of Psychoactive Drugs*, *51*, 343-350. DOI: 10.1080/02791072.2019.1596334
39. Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & **Davis, A. K.** (2019). Inhaled 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT): Supportive context associated with increased positive acute and enduring effects. *Journal of Psychedelic Studies*. DOI: 10.1556/2054.2019.033
40. Uthaug, M. V., Lancelotta, R., Szabo, A., **Davis, A. K.**, Riba, J., & Ramaekers, J. G. (2019). Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgement. *Psychopharmacology. E-pub ahead of print*. DOI: 10.1007/s00213-019-05414-w
41. **Davis, A.K.**, Barrett, F., & Griffiths, R.R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. *Journal of Contextual Behavioral Science*, *15*, 39-45. DOI: 10.1016/j.jcbs.2019.11.004
42. Garcia-Romeu, A., **Davis, A. K.**, Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2020). Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. *Frontiers in Psychiatry – Psychopharmacology*, *10*, 1-16. DOI: 10.3389/fpsy.2019.00955
43. **Davis, A. K.**, Arterberry, B. J., Schneeberger, D., Bonar, E. E., Young, S., Bauermeister, J., Cunningham, R. M., & Walton, M. A. (2020). Evaluation of the dualistic model of passion for alcohol consumption among emerging adults engaged in risky drinking. *Addiction Research and Theory*, *28*, 21-28. DOI: 10.1080/16066359.2019.1571192
44. Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & **Davis, A. K.** (2020). Long-term effect of psychedelic drugs: A systematic review. *Neuroscience & Biobehavioral Reviews*, *113*, 179-189. <https://doi.org/10.1016/j.neubiorev.2020.03.017>
45. Lancelotta, R. & **Davis, A.K.** (2020). Use of benefit enhancement strategies among 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) users: Associations with mystical, challenging, and enduring effects. *Journal of Psychoactive Drugs*, *52*, 273-281.
46. Rosenberg, H., Grant, J., & **Davis, A.K.** (2020). Acceptance of non-abstinence as an outcome goal for individuals diagnosed with substance use disorders: A narrative review of published research. *Journal of Studies on Alcohol and Drugs*, *81*, 405-415.
47. **Davis, A. K.**, Averill, L. A., Basruglia, J. P., Sepeda, N. D., Amoroso, T. (2020). The effectiveness of ibogaine and 5-MeO-DMT treatment for trauma-related psychological and cognitive impairment among United States Special Operations Forces Veterans. *Chronic Stress*, *4*, 1-11.

48. Uthaug, M. V., Lancelotta, R., Ortiz Bernal, A. M., **Davis, A. K.**, & Ramaekers, J. G. (2020). A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting. *Journal of Psychedelic Studies*, 2, 104-113.
49. **Davis, A. K.**, Clifton, J. M., Weaver, E. G., Hurwitz, E. H., Johnson, M. W., & Griffiths, R. R. (2020). Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine (DMT): Phenomenology, interpretation, and enduring effects. *Journal of Psychopharmacology*, 34, 1008-1020.
50. Luoma, J. B., Chwyl, C., Bathje, G. J., **Davis, A. K.**, & Lancelotta, R. (2020). A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. *Journal of Psychoactive Drugs*, 52, 289-299.
51. Dolan, S., Arterberry, B. J., & **Davis, A. K.** (2021). A quadripartite model of passion for marijuana use: Associations with consumption, consequences, craving, and satisfaction with life. *Addiction Research & Theory*, 29, 30-35.
52. **Davis, A. K.**, Barrett, F. S., May, D. G., Sepeda, N., Cosimano, M. P., Finan, P., Johnson M. W., Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy for major depressive disorder: A randomized clinical trial. *JAMA Psychiatry*, 78, 481-489.
53. **Davis, A. K.** Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021). Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. *Journal of Psychopharmacology*, 35, 437-446.
54. Williams, M. T., **Davis, A. K.**, Xin, Y., Sepeda, N. S., Grigas, P. C., Sinnott, S., & Haeny, A. M. (2021). People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. *Drugs: Education, Prevention & Policy*, 28, 215-226.
55. Begun, A. L. Babcock, J., **Davis, A. K.** (2021). Developing your program's substance misuse minor/concentration. *Journal of Social Work Practice in the Addictions*, 21, 202-206.
56. Aday, J., **Davis, A. K.**, Mitzkovitz, C., Bloesch, E., & Davoli, C. (2021). Predicting reactions to psychedelics drugs: A systematic review of states and traits related to acute drug effects. *ACS Pharmacology & Translational Science*, 4, 424-435.
57. Agin-Liebes, G., Haas, T., Lancelotta, R., Uthaug, M., Ramaekers, J., & **Davis, A. K.** (2021). Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. *ACS Pharmacology & Translational Science*, 4, 543-552.
58. Clark, D. A., Arterberry, B. J., Walton, M. A., Cunningham, R. M., Goldstick, J. E., Zimmerman, M. A., **Davis, A. K.**, Bonar, E. E. (2021). Examining same-day associations between cannabis use motives and condom use in urban emerging adults. *Journal of Studies on Alcohol and Drugs*, 82, 516-521.
59. **Davis, A. K.**, Xin, Y., Sepeda, N. D., Garcia-Romeu, A., Williams, M. T. (2021). Increases in psychological flexibility mediate the relationship between acute psychedelic drug effects and decreases in racial trauma symptoms among people of color. *Chronic Stress*, 5, 24705470211035607.
60. Philaw-Kotov, M. L., Walton M. A., Brenneman, B., Gleckman-Krut, M., **Davis, A. K.**, & Bonar, E. E. (2021). What undergraduates want in campus sexual assault prevention programming: Findings from a formative research study. *Journal of American College Health*, online ahead of print.
61. **Davis, A. K.**, Mangini, P., & Xin, Y. (2021). Ketamine-assisted psychotherapy for trauma-exposed patients in an outpatient setting: A clinical chart review study. *Journal of Psychedelic Studies*, 5, 94-102.

62. Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., **Davis, A. K.**, Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., & Barrett, F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. *Translational Psychiatry*, *11*, 574.
63. Uthaug, M. V., **Davis, A. K.**, Haas, T. F., Davis, D. D., Dolan, S. B., Lancelotta, R., Timmermann, C., and Ramaekers, J. G. (2022). The epidemiology of mescaline use: Patterns of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. *Journal of Psychopharmacology*, *36*, 309-320
64. **Davis, A. K.**, Agin-Liebes, G., España, M., Pilecki, B., & Luoma, J. (2022). Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. *Journal of Psychoactive Drugs*, *54*, 309-318.
65. Mangini, P. Averill, L. A., & **Davis, A. K.** (2022). Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans. *Journal of Psychedelic Studies*, *5*, 149-155.
66. Gukasyan, N., **Davis, A.K.**, Barrett, F.S., Cosimano, M.P., Sepeda, N.D., Johnson, M.W., & Griffiths, R.R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective twelve-month follow-up. *Journal of Psychopharmacology*, *6*, 151-158.
67. (Coxe) Hyzak, K. A., Bungler, A., Bogner, J., **Davis, A. K.**, & Corrigan, J. (2022). Implementing Traumatic Brain Injury Screening into Behavioral Healthcare: Protocol for a Prospective Mixed Methods Study. *Implementation Science Communications*, *3*, 17.
68. Reckweg, J. T., Uthaug, M. V., Szabo, A., **Davis, A. K.**, Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022). The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). *Journal of Neurochemistry*, *162*, 128-146.
69. Xin, Y., Espana, M., & **Davis, A. K.** (2022). The acceptability of non-abstinent treatment interventions among clinical social workers in the United States. *Journal of Social Work Practice*, *online ahead of print*.
70. Boehnke, K. F., **Davis, A. K.**, & McAfee, J. (2022). Lessons for the psychedelic highway: Buckle up and build infrastructure. *JAMA Health Forum*, *3*, e221618.
71. Bonar, E. E., Bauermeister, J. A., Blow, F. C., Bohnert, A. S. B., Bourgue, C., Coughlin, L. N., **Davis, A. K.**, Florimbio, A. R., Goldstick, J., Wisnieski, D. M., Young, S. D., & Walton, M. A. (2022). A randomized controlled trial of social media interventions for risky drinking among adolescents and emerging adults. *Drug and Alcohol Dependence*, *online ahead of print*.
72. de la Salle, S., Gran-Ruaz, S., Davis, D. D., **Davis, A. K.**, & Williams, M. T. (2022). Acute and enduring effects of psychedelic use among Indigenous peoples in Canada and the United States. *Canadian Psychology: Building a socially and culturally responsive psychology*, *63*, 589-607.
73. Clifton, J. M., Belcher, A. M., Greenblatt, A. D., Welsh, C. M., Cole, T. O., & **Davis, A. K.** (2022). Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder. *Journal of Psychedelic Studies*, *6*, 80-87.
74. **Davis, A. K.**, Arterberry, B. J., Xin, Y., Agin-Liebes, G., Schwarting, C., & Williams, M. T. (2022). Race, ethnic, and sex differences in prevalence of and trends in hallucinogen consumption among lifetime users in the United States between 2015-2019. *Frontiers in Epidemiology*, *2*, 876706.
75. Levin, A., Nagib, P.B., Deiparine, S., Gao, T., Mitchell, J., & **Davis, A.K.** (2022). Perceptions of Psychoactive Drugs among Psychiatrists in the United States: The Impact of National Drug Policy. *International Journal of Drug Policy*, *online ahead of print*.

76. Luoma, J.B., Pilecki, B., **Davis, A.K.**, Smith, S.M. (2022). Predictors of attitudes toward psychedelics among psychologists in the USA. *Drugs: Education, Prevention & Policy*, online ahead of print.
77. Xin, Y., Schwarting, C., Nagib, P., Armstrong, S., Bonar, E. E., Arterberry, B. J., & **Davis, A. K.** (2022). Increases in cannabis use during COVID-19 pandemic associated with cannabis use disorder (CUD) symptoms, consequences, and amphetamine misuse among college students with CUD. *Journal of Social Work Practice in the Addictions*, online ahead of print.
78. Ortiz, A. M., Raison, C. L., Lancelotta, R., Davis, A. K. (2022). Reactivations after 5-MeO-DMT use in naturalistic settings: An initial exploratory analysis of the phenomenon's predictors and its emotional valence. *Frontiers in Psychiatry*, 13:1049643.
79. Glynos, N. G., Pierce, J., **Davis, A. K.**, McAfee, J., & Boehnke, K. F. (2023). Knowledge, perceptions, and use of psychedelics among individuals with fibromyalgia. *Journal of Psychoactive Drugs*, 55, 73-84.
80. Ching, T. H. W., **Davis, A. K.**, Xin, Y., Williams, M. T. (2023). Effects of Psychedelic Use on Racial Trauma Symptoms and Ethnic Identity among Asians in North America. *Journal of Psychoactive Drugs*, 55, 19-29.
81. Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & **Davis, A. K.** (2023). Subtypes of the Psychedelic Experience have Reproducible and Predictable Effects on Depression and Anxiety Symptoms. *Journal of Affective Disorders*, 324, 239-249.
82. Armstrong, S. A., Xin, Y., Sepeda, N. D., Polanco, M., Averill, L. A., & Davis, A. K. (2023). Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans. *Military Psychology*, online ahead of print.
83. Haeny, A. M., Lopez, J., Colon-Grigas, P., Crouch, M., **Davis, A. K.**, Williams, M. T. (2023). Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among people with racial and ethnic minoritized identities in the United States and Canada. *Journal of Substance Use and Addiction Treatment*, 149:209035.
84. **Davis, A. K.**, Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023). Examining the safety and clinical efficacy of psilocybin therapy for Veterans with PTSD: An open-label proof-of-concept trial. *BMJ Open*, 13, e068884.
85. **Davis, A. K.**, Timmerman, C., Ortiz Bernal, A. M., Lancelotta, R., Nayak, S., Nikolaidis, A., & Griffiths, R. R. (In Press). Translation and initial psychometric evaluation of Spanish versions of three psychedelic acute effects measures: Mystical, challenging and insight experiences. *Journal of Psychoactive Drugs*.
86. **Davis, A.K.**, Xin, Y., Sepeda, N., Averill, L.A. (In Press). Consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed Special Operations Forces Veterans: Prospective data from a clinical program in Mexico. *American Journal of Drug and Alcohol Abuse*.
87. Armstrong, S. B., Levin, A. W., Xin, Y., Horan, J. C., Luoma, J., Nagib, P., Pilecki, B., & **Davis, A. K.** (In Press). Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States. *Journal of Psychedelic Studies*.
88. Simonsson, O., Calbring, P., Carhart-Harris, R., **Davis, A. K.**, Nutt, D. J., Erritzoe, D., & Goldberg, S. B. (In Press). Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: An individual participant data meta-analysis. *Psychiatry Research*.
89. Xin, Y., Armstrong, S. B., Averill, L. A., Sepeda, N., & **Davis, A. K.** (In Press). Predictors of psychedelic treatment outcomes among Special Operations Forces Veterans. *Psychology of Consciousness: Theory, Research, and Practice*.

90. **Davis, A. K.**, Arterberry, B. J., Xin, Y., Hubbard, S. M., Schwarting, C. M., & Bonar, E. E. (In Press). Incremental predictive validity of the Dualistic Model of Passion for cannabis use among college undergraduate students with and without a cannabis use disorder. *Cannabis*.
91. (Coxe) Hyzak, K. A., Bunger, A. C., Bogner, J., **Davis, A. K.**, Corrigan, J. D. (In Press). Implementing traumatic brain injury screening in behavioral health treatment settings: Results of an explanatory sequential mixed methods investigation. *Implementation Science*.

Manuscripts Under Review

1. Barrett, F. S., Doss, M. K., Sepeda, N. D., **Davis, A. K.**, Finan, P. H., Pekar, J. J. & Griffiths, R. R. (Revise & Resubmit). Effects of psilocybin therapy on amygdala reactivity in patients with major depressive disorder. *Journal of Affective Disorders*.
2. Xin, Y., Schwarting, C., Wasef, M., & **Davis, A. K.** (Under Review). Exploring the intersectionality of stigma and substance use help-seeking behaviors among LGBTQ+ individuals: A systematic review. *Trauma, Violence, & Abuse*.
3. Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., **Davis, A. K.** (Under Review). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for Major Depressive Disorder. *PLOS One*.
4. Aday, J., Bloesch, E., Davis, A. K., Domoff, S., Scherr, K., Woolley, J., & Davoli, C. (Revise and Resubmit). Increases in aesthetic experience following ayahuasca use: An open-label, naturalistic study. *Journal of Humanistic Psychology*.
5. Aday, J., Bloesch, E., Davis, A. K., Domoff, S., Scherr, K., Woolley, J., & Davoli, C. (Under Review). Effects of ayahuasca on gratitude and relationships with nature: An open-label, naturalistic study. *Journal of Psychoactive Drugs*.

GRANTS

EXTRAMURAL Funding

Previous

- | | |
|-------------|--|
| 2016 – 2017 | Multidisciplinary Alcoholism Research Training Program
Grant#: T32AA007477
Sponsor: NIH/NIAAA
Total Direct Costs: \$53,935.00
Principal Investigator: Frederic Blow, Ph.D.
Role: Postdoctoral Fellow, 100% FTE |
| 2017 – 2019 | Human Behavioral Pharmacology of Substance Abuse
Grant#: T32DA007209
Sponsor: NIH/NIDA
Total Direct Costs: \$107,863.00
Principal Investigator: George Bigelow, Ph.D.
Role: Postdoctoral Fellow, 100% FTE |
| 2019 – 2021 | Naturalistic Psychedelic Use and Coping with Ethnic Discrimination: A Survey of People of Color
Sponsor: University of Ottawa
Total Direct Costs: \$9,960.00
Role: Co-Co-Principal Investigator (with Monnica Williams at University of Ottawa) |
| 2020 – 2021 | Retrospective Measurement of Clinical Outcomes of Cannabis- & Ketamine-assisted Psychotherapy |

- Sponsor: Innate Path
 Total Direct Costs: \$8,182.00
 Role: Principal Investigator
- 2020 – 2021 The Role of Stigma for Psychedelic Substance Use Among Psychologists in the United States
 Sponsor: Portland Psychotherapy Institute
 Total Direct Costs: \$9,091.00
 Role: Principal Investigator
 Co-investigators: Jason Luoma, Brian Pilecki
- 2020 – 2021 Prospective clinical chart review study of Special Operations Forces Veterans receiving ibogaine and 5-MeO-DMT treatment in Mexico
 Sponsor: Veterans Exploring Treatment Solution
 Total Direct Costs: \$21,895
 Role: Principal Investigator
- 2021 – 2023 Safety and efficacy of psilocybin-assisted therapy for patients with fibromyalgia
 Sponsor: Tryp Therapeutics (to University of Michigan)
 Total Direct Costs: Part 1: \$6,764; Part 2: \$18,574
 Role: Co-investigator (Sub-award)
- 2022 – 2023 Development and pilot testing of a global ibogaine patient registry (Year 1)
 Sponsor: Herbert W Hoover Foundation
 Total Direct Costs: \$150,000
 Role: Principal Investigator
 Co-investigator: Stacey Armstrong; Deborah Mash
- Current**
- 2019 – 2024 Center for Psychedelic and Consciousness Research, Johns Hopkins University
 Sponsor: The Steven and Alexandra Cohen Foundation, Tim Ferriss, Craig Nerenberg, Matt Mullenweg, and Blake Mycoskie
 Total Costs: \$17,000,000.00
 Role: Clinical Consultant/Adjunct Faculty
 Co-investigator: Lynnette A. Averill (Yale University/NCPTSD)
- 2021 – 2025 Fund for Psychedelic Drug Research and Education, Ohio State University
 Sponsors: Anonymous Private Donor (\$750,000) & Matching Anonymous Donor in the name of Peter and Barbara (\$750,000)
 Total Costs: \$1,500,000
 Role: Fund Director and Principal Investigator
- 2022 – 2024 Prospective examination of the effectiveness of legal psychedelic-assisted treatment approaches for Special Operations Forces Veterans in the United States
 Sponsor: Veterans Exploring Treatment Solution
 Total Direct Costs: \$190,738
 Role: Principal Investigator
 Co-investigator: Lynnette A. Averill (Yale University/NCPTSD)
- 2023 – 2024 Global ibogaine patient registry: Recruitment and data collection (Year 2)
 Sponsor: Herbert W Hoover Foundation
 Total Direct Costs: \$99,811
 Role: Principal Investigator
 Co-investigator: Stacey Armstrong; Deborah Mash

2023 – 2025 Consultation and training in psilocybin-assisted therapy for Veterans with PTSD
Sponsor: Baylor College of Medicine
Total Direct Costs: \$69,049
Role: Principal Investigator
Co-investigator: Stacey B. Armstrong (OSU); Lynnette A. Averill (Baylor)

Submitted

Unfunded

2021-2022 Examination of the super long-term outcomes of MDMA-assisted therapy trial participants
Sponsor: Multidisciplinary Association of Psychedelic Studies
Total Direct Costs: \$32,960
Role: Principal Investigator

2023 – 2025 Proposal for travel support – OSU psilocybin trial for Veterans with PTSD
Sponsor: Veterans Exploring Treatment Solutions
Total Direct Costs: \$99,936
Role: Principal Investigator

INTRAMURAL Funding

Previous

2013 – 2014 Using the theory of planned behavior to predict employing harm reduction strategies among MDMA/ecstasy users
Sponsor: Bowling Green State University Graduate College – Competitive Dissertation Fellowship
Total Direct Costs: \$15,500
Role: Principal Investigator

2016 – 2017 Survey of Addiction Treatment Workforce in Ukraine
Sponsor: Fogarty Program, University of Michigan (D43TW009310)
Total Direct Costs: \$11,169
Role: Principal Investigator

2019 – 2020 The Impact of National Drug Policies on the Acceptability and Availability of Non-abstinent Treatment Interventions Among Clinical Social Workers in the United States
Sponsor: Drug Enforcement and Policy Center, The Ohio State University
Total Direct Costs: \$10,000
Role: Principal Investigator
Co-investigator: Yitong Xin, MBA, MSW (Graduate Student in College of Social Work, OSU)

2020 – 2021 A Survey of Spanish-speakers Who Have Had a Psychedelic Experience with Mescaline/Peyote/San Pedro, psilocybin, 5-MeO-DMT, or LSD
Sponsor: Center for Psychedelic and Consciousness Research – Johns Hopkins University
Total Direct Costs: \$15,000
Role: Principal Investigator
Co-investigators: Anny Ortiz, Christopher Timmerman, Rafael Lancelotta, Sandeep Nayak

2020 – 2021 Perceptions of Psychoactive Drugs among Psychiatrists in the United States: The Impact of National Drug Policy
Sponsor: Drug Enforcement and Policy Center, The Ohio State University
Total Direct Costs: \$6,715
Role: Principal Investigator

Co-investigators: Adam Levin (Psychiatry Resident in College of Medicine, OSU); Paul Nagib (Medical Student in College of Medicine, OSU)

2021 – 2023 Longitudinal examination of passion for cannabis use among college undergraduate students with and without a cannabis use disorder
Sponsor: College of Social Work Seed Grant Program – The Ohio State University
Total Direct Costs: \$16,473
Role: Principal Investigator

Current

2023 – 2025 Examining the safety, acceptability, and preliminary efficacy of psychedelic-assisted therapy for lung cancer patients with depression and anxiety: A proof-of-concept trial
Sponsor: OSU Comprehensive Cancer Center Intramural Research Program (Pelatonia)
Total Direct Costs: \$199,577
Role: Co-Principal Investigator (with Theodore Wagener)
Co-investigators: Barbara Anderson; Peter Shields; Stacey Armstrong

Submitted

Unfunded

2023 – 2024 Building community engagement in psilocybin-therapy training for BIPOC clinicians in central Ohio
Sponsor: Office of Outreach and Engagement
Total Direct Costs: \$19,961
Role: Principal Investigator

Grant Review committees

2018 - Present Source Research Foundation Student Grant Program

2020 Health Research Board – Ireland

2020 National Science Centre – Poland

2021 - Present Source Research Foundation Community Grant Program

2022 Graduate Women in Science

2022 - Present Source Research Foundation Travel Award Grant Program

2023 French National Research Agency

2023 The Ohio State University T32 pre-doctoral Training Program

2023 The Ohio State University Good-to-Great Grants Program

2023 Switzerland National Science Foundation

CLINICAL ACTIVITIES

Certification

2008 – Present Certified Chemical Dependency Counselor
North Carolina (#2348: 2008-2011)
Ohio (#101134: 2010-2014)
Michigan (#2-01276: 2014-2018)

Maryland (#C4298: 2017-Present)

Licensure

- 2016 – 2018 Psychologist - Limited License Doctoral (Michigan: #6301016896)
- 2018 – Present Psychologist (Maryland #05932)
- 2021 – Present Psychologist (Ohio #P.08123)
- 2021 – Present Licensed Independent Chemical Dependency Counselor (Ohio #LICDC.162163)

Clinical Responsibilities

- 2005 – 2009 Paraprofessional, Addiction Counselor, Director of Treatment Services
McLeod Addictive Disease Center, Charlotte, NC.
- 2010 – 2014 Psychology Trainee
Psychological Services Center, Bowling Green, OH.
Sandusky County Board of Developmental Disabilities, Fremont, OH.
Elmwood Long-term Acute Care Hospital, Green Springs, OH.
- 2014 – 2015 Clinical Trial Therapist for Substance Use Disorder Intervention Study
VA HSR&D Center for Clinical Management Research
Ann Arbor VA Healthcare Center, Ann Arbor, MI.
- 2014 – 2015 Psychology Practicum Student
Substance Use Disorders Clinic & Intensive Outpatient Programs
Ann Arbor VA Healthcare Center, Ann Arbor, MI.
- 2016 – 2017 Clinical Postdoctoral Fellow
Substance Use Disorders Clinic
Ann Arbor VA Healthcare System, Ann Arbor, MI
- 2017 – 2019 Clinical Trial Therapist on Psychedelic Drug Administration Studies
Behavioral Pharmacology Research Unit
Department of Psychiatry & Behavioral Sciences
Johns Hopkins University School of Medicine, Baltimore, MD
- 2019 – Present Clinical Trial Therapist Supervisor/Consultant
Center for Psychedelic and Consciousness Research
Behavioral Pharmacology Research Unit
Department of Psychiatry & Behavioral Sciences
Johns Hopkins University School of Medicine, Baltimore, MD

EDUCATIONAL ACTIVITIES

Teaching

Undergraduate instruction

- 2010 – 2012 Lecturer/Teaching Assistant, Bowling Green State University
Abnormal Psychology (Fall 2010, Spring 2011)
Introduction to Psychology (Fall 2011, Spring 2012)
- 2019 – Present Instructor, The Ohio State University
Introduction to Psychopathology and Social Work Practice (Fall 2019, Spring 2020)
Research & Statistics for Understanding Social Work Problems and Diverse Pop. (Fall 2020)
Psychedelic Studies: Neurochemistry, Plants, Fungi, and Society (Fall 2020)

Course Creation/Development: Trauma 101 (2020-2021)
Honor's Thesis Research (Fall 2020, Spring 2021)
Guest Lecturer: Psychedelic Studies: Neurochemistry, Plants, Fungi, and Society (Spring 2021)
Course Creation/Development: Intervening with Individuals Regarding Substance Misuse (2021)
Research & Statistics for Understanding Social Work Interventions (Spring 2021, Spring 2022)

Graduate instruction

2020 – Present Instructor, The Ohio State University
Research Methods in Social Work (Spring 2023)
Independent Study: Psychedelic Science
Dissertation Study: Yitong Xin
Course Revision/Update: Methods for Social Work Research (8401)
Methods for Social Work Research (Spring 2023)

Clinical instruction

2012 Guest Lecturer, Elmwood at the Springs long-term acute care hospital
Title: *Behavioral Medicine, Mental Health, and the Importance of Self-Care in the Helping Professions*. (Co-Presenter: Jacob Burmeister) Title: *Strategies for managing dementia-related behaviors in medical settings*. (Co-Presenter: Margaret Feuille)

2016 – 2017 Clinical Consultant/Trainer in Evidenced-Based Therapies at the Substance Use Disorders Clinic – Ann Arbor VA Healthcare Center
Lindsey Beach, MSW

2020 – Present Lead Trainer – Fluence: Education in Psychedelic-assisted Psychotherapy and Integration
Course: Integrating Psychedelics with Evidenced-Based Therapies (Summer 2021; Fall 2021; Spring 2022; Fall 2022; Spring 2023)

2021 – Present Faculty Presenter – Integrative Psychiatry Institute: Psilocybin Therapy for people with Major Depressive Disorder (Spring 2022; Spring 2023; Summer 2023)

Workshops /seminars

2013 Seminar Presentation, Counseling Center Staff at Bowling Green State University. Title: *Clinical Application of Expressive Writing in a College Counseling Center*. (Co-Presenters: Nicole Cross, Brent Lang, Kirsten Lauritsen, Harold Rosenberg)

2017 Workshop, Motivational Interviewing: Two Day Training for Outpatient Psychiatry Clinicians Trainees, Research Staff, and Michigan Medicine clinicians, Department of Psychiatry, University of Michigan. (Co-Trainers: Erin E. Bonar, Dan DeSena, Chamisa Mackenzie)

2018 Seminar Presentation, Midwest Psychedelic Therapy Symposium (Madison, WI). Title: *Discussing psychedelic experiences in psychotherapy: A primer for clinicians*. (Co-presenter: Rafael Lancelotta)

2019 Workshop, Motivational Interviewing in Clinical Research: One Day Training for Clinical Research Staff at Johns Hopkins University, Department of Psychiatry and Behavioral Sciences.

2020 Workshop, Discussing Psychedelic Experiences in Psychotherapy: Two Day Training for Psychiatry Faculty and Staff at the University of Utah, Department of Psychiatry. (Co-trainers: Mary Cosimano, Rafael Lancelotta).

2021 January Workshop, Motivational Interviewing in Clinical Research: Two Day Training for Clinical Research Staff at Johns Hopkins University, Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research.

- 2021 March Workshop, Motivational Interviewing in Clinical Research: Two Day Training for Clinical Research Staff at Johns Hopkins University, Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research.
- 2022 Psilocybin-assisted psychotherapy: Background, Current Research, and Basic Skills Psychedemia pre-conference workshop at The Ohio State University. (Co-trainers: Natalie Gukasyan and Diana Quinn).
- 2023 Psychedelics: Evolving Science, Clinical Perspectives, and Ethical Considerations Food and Drug Administration

Mentoring

Pre-doctoral Advisees /Mentees

- 2013 – 2014 Clinical Supervisor of practicum students at Bowling Green State University
Nicole Cross, Ph.D. & Debbie Hoffman, Ph.D.
- 2013 – 2019 Supervisor for undergraduate research study students
BGSU: Breanne Hitchen
UC Denver: Elise Renn
Johns Hopkins University: Shannon Gavin
- 2015 – 2016 Clinical Supervisor of practicum student at VA Maryland
Brenton Roman, Ph.D.
- 2017 – 2019 Research Supervisor for graduate students
U. Wyoming: Rafael Lancelotta
Yale Medical School: Marley Windham-Herman
California Institute of Integral Studies: Amanda Stevenson, Bryan Avila, Angela Ward
Johns Hopkins School of Medicine: Eric Weaver
- 2018 – 2019 Clinical Supervisor of externship student at Johns Hopkins University
Behavioral Pharmacology Research Unit
Kasey Cox (Master’s degree completed May 2019)
- 2020 – 2021 Cariah Cox, BSSW, The Ohio State University College of Social Work – Honor’s Thesis
Title: Examining transits, barriers, and needs for young black Americans in central Ohio with a history of incarceration.

Master’s thesis committees

- 2017 – 2018 Sara So, MHS, Johns Hopkins University School of Public Health.
Title: 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
- 2018 – 2019 Pria Islam, MHS, Johns Hopkins University School of Public Health.
Title: Motives for Marijuana Use: A Review

PhD candidacy exam committee

- 2020 Katheryn Coxe, The Ohio State University, College of Social Work (CSW Faculty Member)
- 2021 Christine Sielski, The Ohio State University, College of Social Work (CSW Faculty Member)
- 2021 Yitong Xin, The Ohio State University, College of Social Work (CSW Faculty Chair)

PhD students

- 2019 – Present Yitong Xin, The Ohio State University, College of Social Work (Faculty Mentor)
- 2019 – Present Anny Ortiz, University of Wisconsin – Madison, Department of Human Ecology (External Mentor)
- 2020 – 2023 Katheryn Coxe, The Ohio State University, College of Social Work (Committee Member; Current Position: Postdoctoral Fellow at The Ohio State University)
- 2020 – 2022 Jacob Aday, Central Michigan University, Department of Psychology (External Mentor; Current Position: Instructor at the University of Michigan)
- 2021 – Present Raffaele Lancelotta, The Ohio State University, College of Social Work (Faculty Mentor)

Postdoctoral Fellows

- 2020 – Present Adam Levin, The Ohio State University, Department of Psychiatry and College of Social Work (Faculty Mentor)
- 2021 – 2023 Stacey B. Armstrong, The Ohio State University, College of Social Work (Faculty Mentor; Current Position: Senior Researcher at The Ohio State University)
- 2023 – Present Meghan DellaCrosse, The Ohio State University, College of Social Work (Faculty Mentor)

ORGANIZATIONAL ACTIVITIES

Institutional Appointments

- 2018 – 2019 Johns Hopkins University Senior Postdoctoral Fellow/Postdoc Representative
Behavioral Pharmacology Research Unit

Professional Societies

Current

- 2009 – Present Regular Member, American Psychological Association
- 2012 – Present Regular Member, College on Problems of Drug Dependence
- 2019 – Present Member, Society for Social Work Research

Previous

- 2010 – 2015 Student Member, National Association of Alcoholism and Drug Addiction Counselors
- 2015 – 2019 Professional Member, Association for Behavioral and Cognitive Therapies
- 2016 – 2017 Postdoctoral Fellow, Research Society on Alcoholism

RECOGNITION

Awards, Honors

- 2012 BGSU Distinguished Thesis Award (Nominee)
- 2012 BGSU Letter of Commendation, Department of Psychology
- 2013 BGSU Donald B. Leventhal Memorial Award, Department of Psychology
- 2014 BGSU Katzner Award for Graduate Student Research
- 2016 Outstanding Presentation, U. of Maryland School of Medicine
- 2019 CPDD Award for Early Career Investigators
- 2020 College of Social Work Undergraduate Faculty Excellence in Teaching Award
- 2021 College of Social Work Tony Tripodi Prize for Research Excellence

Invited Talks

Institutional

- 2018 Mind the Gap Series at Johns Hopkins University School of Medicine (Baltimore, MD). Title: *The Role of Psilocybin-assisted Psychotherapy in the Treatment of Major Depressive Disorder*. (Co-presenter: Natalie Gukasyan, MD)

2020 Consciousness Research Interests Group at The Ohio State University College of Medicine (Columbus, OH). Title: *Breakthrough treatment for Major Depressive Disorder: Psilocybin-Assisted Therapy.*

National & International

2017 Usona Institute (Madison, WI). Title: *5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT): Patterns of use, acute subjective effects, and motivations for consumption.*

2017 Capacity Building for Lifespan Focused Substance Use Disorder. Research in Ukraine Workshop (Ann Arbor, MI & Kiev, Ukraine). Title: *Introduction to Motivational Interviewing: Basic Skills Building Teleconference Presentation.*

2018 Yale University Medical School (New Haven, CT). Title: *The epidemiology and therapeutic potential of 5-MeO-DMT.*

2018 DMT Dialogues: The Tyringham Initiative (New York, NY). Title: *DMT Entity Encounters: Results from an International Survey.*

2019 University of Michigan Psychedelic Neuroscience Symposium (Ann Arbor, MI). Title: *Quantum change occasioned by psychedelics in laboratory and naturalistic settings.*

2019 University of Utah Medical School, Grand Rounds (Salt Lake City, UT). Title: *Quantum change occasioned by psilocybin-assisted psychotherapy for Major Depressive Disorder: Primary outcomes and a case report.*

2019 The Mt. Tam Psilocybin Summit (Virtual Internet Conference). Title: *Quantum Change: Exploring the role of personal insight experiences occasioned by psilocybin.*

2019 Horizons – Perspectives on Psychedelics (New York City, NY). Title: *The potential for healing and harm with 5-MeO-DMT.*

2019 Naropa University (Boulder, CO). Title: *Power and privilege in psychedelic spaces: Clinical work, research, and community.*

2020 University of Michigan Student Association for Psychedelic Studies (Ann Arbor, MI). Title: *Psychedelic science: Navigating power and privilege in clinical and academic settings*

2020 Central Michigan University Department of Psychological Sciences (Mt. Pleasant, MI). Title: *Primary clinical and neuroimaging outcomes from a trial investigating psilocybin-assisted psychotherapy for Major Depressive Disorder*

2020 University of Michigan Student Association for Psychedelic Studies (Ann Arbor, MI). Title: *Discussing psychedelic experiences in psychotherapy: Preparation and integration of psilocybin sessions in a clinical trial*

2020 University of Texas Health, Grand Rounds (Houston, TX – Virtual Talk). Title: *Mental health outcomes of psychedelics administered in laboratory and naturalistic settings.*

2020 Psych Congress Annual Meeting (Nashville, Tennessee – Virtual Talk). Title: *Psilocybin therapy for the treatment of Major Depressive Disorder.*

2020 The Mt. Tam Psilocybin Summit (Virtual Internet Conference). Title: *Psilocybin therapy for the treatment of Major Depressive Disorder: Primary and long-term outcomes of a randomized clinical trial.*

2020 Boston Psychedelic Research Group (Speaker Series – Virtual Talk). Title: *People of color who experience racial trauma report decreases in mental health symptoms after naturalistic psychedelic use.*

2021 Portland Psychotherapy Institute (TRIPS Speaker Series – Virtual Talk). Title: *What does Psilocybin-Assisted Therapy for Depression Look Like? A Clinical Case Presentation based on a Recent Clinical Trial from Johns Hopkins.*

- 2021 Mt Sinai Icahn School of Medicine – Center for Psychedelic Psychotherapy and Trauma Research (Speaker Series – Virtual Talk). Title: *Black, Indigenous, and People of Color who use psychedelics to heal racial trauma.*
- 2021 SXSW Festival (Panel Presentation – Virtual Recording). Title: *Psychedelics - Rewiring Mental Health Care.*
- 2021 Higher Education Center for Alcohol and Drug Misuse Prevention and Recovery (Webinar – Virtual). Title: *Understanding Psychedelics: State of the Science and Policy Changes in the United States.*
- 2021 Sacred Plants in the Americas II (Panel Presentation - Virtual). Title: *Toad Medicine: The Science, Myths, and New Culture of 5-MeO-DMT.*
- 2021 National Register of Health Service Psychologists (Webinar – Virtual). Title: *The what, why, and how of psilocybin-assisted therapy*
- 2021 Taking a Trip: Psychedelic-Assisted Therapies in Healthcare at Ohio Health System (Webinar – Virtual). Title: *Psilocybin therapy: A new treatment for major depressive disorder.*
- 2021 Panel Presentation for National Recovery Month at the College of Social Work OSU (Webinar – Virtual). Title: *What's old is new again: The possibility of psychedelics in mental health treatment.* Co-presenters: Rafael Lancelotta, Yitong Xin, Diana Quinn, Patti Zettler.
- 2021 Alta Bates Summit Medical Center, Grand Rounds (Virtual). Title: *Treating Depression with Psilocybin-assisted Therapy.*
- 2021 Insight Conference (Virtual). Title: *The importance of diversity in psychedelic science: A global call to academics.*
- 2023 Rowan College (Virtual). Title: *Adverse and therapeutic effects associated with 5-MeO-DMT experiences.*
- 2023 Ohio Health (Columbus, OH). Title: *Psilocybin-assisted therapy for Major Depressive Disorder.*
- 2023 Dickenson College (Carlisle, PA). Title: *Psychedelic-assisted psychotherapy: A promising intervention for mental health treatment.*
- 2023 Psychedelic Science & Advocacy (Louisville, KY). Title: *The necessity of interdisciplinary education in psychedelic science.*
- 2023 Arizona State University – Project ECHO (Virtual). Title: *Psychedelics as a medication-assisted therapy for people with substance misuse and use disorder.*
- 2023 Addiction Studies Institute (Virtual). Title: *Psychedelic-assisted therapy and addiction: An emerging treatment paradigm.* Co-presenters: Stacey Armstrong and Adam Levin.
- 2023 American Association for the Advancement of Science: SciLine Media Briefing on Psychedelic Drug Therapies. Title: *Psilocybin-assisted Therapy for Depression: Clinical Outcomes and Future Directions.*
- 2023 The Department of Veterans Affairs Office of Mental Health and Suicide Prevention (OMHSP) and Office of Research and Development (ORD) State-of-the-Art (SOTA) conference on Psychedelic Treatments for Mental Health Conditions (Virtual). Title: *Psilocybin-assisted therapy for veterans diagnosed with PTSD: Preliminary findings from an open-label trial.*

OTHER PROFESSIONAL ACCOMPLISHMENTS

Posters

Published Conference Abstracts

1. **Davis, A.K.** & Rosenberg, H. (June, 2012). *Development and initial evaluation of an Ecstasy Craving Questionnaire*. Poster presentation at the Annual Meeting & Scientific Sessions of the College on Problems of Drug Dependence, Palm Springs, CA.
2. **Davis, A.K.**, Ashrafioun, L., Cross, N., Rosenberg, H., Leith, J., Osborn, L.A., ... Baik, K.D. (June, 2013). *Development and evaluation of the Marijuana Use Reduction Self-Efficacy Scale*. Poster presentation at the Annual Meeting & Scientific Sessions of the College on Problems of Drug Dependence, San Diego, CA. Published in *Drug and Alcohol Dependence*, 140, January 2014, e44.
3. Ashrafioun, L., Hawley, A., Kraus, S., Kryszak, L., Cross, N., **Davis, A.K.**, ... Jesse, S (June, 2013). *Development and initial evaluation of an instrument for measuring self-efficacy to reduce marijuana use-related harm*. Poster presentation at the Annual Meeting & Scientific Sessions of the College on Problems of Drug Dependence, San Diego, CA. Published in *Drug and Alcohol Dependence*, 140, January 2014, e7-e8.
4. **Davis, A.K.**, Cross, N., Lauritsen, K., Rosenberg, H., Ashrafioun, L., Osborn, L.A., ... Leith, J. (June, 2014). *Psychometric evaluation of the Marijuana Reduction Strategy Self-Efficacy Scale with a community sample of marijuana users*. Poster presentation at the Annual Meeting & Scientific Sessions of the College on Problems of Drug Dependence, San Juan, PR. Published in *Drug and Alcohol Dependence*, 146, January 2015, e258-e259.
5. Lauritsen, K., **Davis, A.K.**, Cross, N., Osborn, L.A., Rosenberg, H., Lang, B., ... Baik, K. (June, 2014). *Reported use of non-prescribed marijuana for biomedical and psychiatric conditions among regular marijuana users*. Poster presentation at the Annual Meeting & Scientific Sessions of the College on Problems of Drug Dependence, San Juan, PR. Published in *Drug and Alcohol Dependence*, 146, January 2015, e170.
6. **Davis, A.K.**, Bonar, E.E., Schneeberger, D., Bourque, C., Bohnert, A. S. B., Cunningham, R., & Walton, M., (September, 2017). *Understanding Drinking among Emerging Adults using the Dualistic Model of Passion: Associations with Alcohol Consumption, Blackouts, and Overdose*. Poster Presentation at The 6th Society for Advancement of Violence and Injury Research National Conference, Ann Arbor, MI.
7. **Davis, A.K.**, Bonar, E.E., Goldstick J., Walton, M., Winters, J., & Chermack, S. (June, 2017). *Binge drinking and non-partner violence is associated with recent gambling among veterans in VA outpatient mental health treatment*. Poster presented at the 40th annual conference of the Research Society on Alcoholism, Denver, CO.
8. Goldstick, J., Bohnert, K., **Davis, A.K.**, Cunningham, R., Walton, M. (June, 2017). *Dual trajectories of mental health and alcohol use among drug-using youth presenting to an urban ED: social influences and longitudinal violence outcomes*. Poster presented at the 40th annual conference of the Research Society on Alcoholism, Denver, CO.
9. **Davis, A.K.**, Walton, M., Bohnert, K. M., Bourque, C., & Ilgen, M. (June, 2017). *Factors associated with alcohol consumption among medical cannabis patients with chronic pain*. Poster presented at the 40th annual conference of the Research Society on Alcoholism, Denver, CO.
10. Bonar, E. E., Cunningham, R. M., Arterberry, B. J., **Davis, A. K.**, & Walton, M. A. (June, 2017). *Blackouts among Risky Drinking Adolescents: Associations with sexual assault, peer influences, and substance use*. Poster presented at the 40th annual conference of the Research Society on Alcoholism, Denver, CO.
11. Arterberry, B. J., **Davis, A. K.**, Walton, M. A., Cunningham, R. M., Blow, F. C., & Bonar, E. E. (June, 2017). *Associations of marijuana quantity and frequency with marijuana motives and consequences among emerging adults*. Poster presented at the 79th annual conference of the College on Problems of Drug Dependence, Montreal, Canada
12. **Davis, A.K.**, Barsuglia, J. P., Lancelotta, R., Grant, R., & Renn, E. (June, 2018). *5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT): Patterns of use, motives for consumption, and acute subjective effects*. Poster presentation at the 80th annual conference of the College on Problems of Drug Dependence, San Diego, CA.

13. Arterberry, B. J., **Davis, A. K.**, Bonar, E. E., Walton, M. A., & Blow, F. C. (June, 2018). *Predictors of empirically-derived substance use patterns of sexual minority groups presenting to an urban emergency department*. Poster presentation at the 80th annual conference of the College on Problems of Drug Dependence, San Diego, CA.
14. **Davis, A.K.** & Arterberry, B. J. (June, 2019). *Examining a quadripartite model of passion for marijuana use: Associations with consumption, consequences, craving, and satisfaction with life*. Poster presentation at the 81st annual conference of the College on Problems of Drug Dependence, San Antonio, TX.
15. **Davis, A.K.**, Arterberry, B.J., Xin, Y., Agin-Leibes, G., & Williams, M.W. (June, 2021). *Race, ethnic, and sex differences in prevalence of hallucinogen consumption among lifetime users in the United States*. Poster presentation at the 83rd annual conference of the College on Problems of Drug Dependence, Virtual.
16. Klesel, B.C., Vidales, C., **Davis, A.K.**, Schwarting, C.M., & Arterberry, B.J. (June, 2021). *Social support networks: Protective factors for marijuana frequency and marijuana problems in adolescence*. Poster presentation at the 83rd annual conference of the College on Problems of Drug Dependence, Virtual.
17. Schwarting, C.M., Weddell, R.D., **Davis, A.K.**, Klesel, B.C., & Arterberry, B.J. (June, 2021). *Treatment seeking for alcohol and marijuana use disorder: The influence of religiosity and psychological distress*. Poster presentation at the 83rd annual conference of the College on Problems of Drug Dependence, Virtual.
18. Haeny, A., Lopez, J., Grigas, P.C., Crouch, M., Williams, M.W., & **Davis, A.K.** (June, 2021). *The associations of psychedelic experiences and other substance use among people of color with a history of racial trauma*. Poster presentation at the 83rd annual conference of the College on Problems of Drug Dependence, Virtual.
19. Xin, Y., Mangini, P., & **Davis, A.K.** (June, 2021). *A retrospective chart review study of cannabis and ketamine-assisted psychotherapy for trauma-exposed clients in an outpatient clinic*. Poster presentation at the 83rd annual conference of the College on Problems of Drug Dependence, Virtual.
20. Xin, Y., Arterberry, B.A., Schwarting, C., Armbstrong, S.A., Bonar, E.E., & **Davis, A.K.** (June, 2022). *Longitudinal examination of obsessive passion for cannabis use among college undergraduate students*. Poster presentation accepted for the 84th annual conference of the College on Problems of Drug Dependence, Minneapolis, MN.
21. **Davis, A.K.**, Levin, A., Nagib, P., Deiparine, S., Gao, T., & Mitchell, J. (June, 2022). *The Impact of National Drug Policy on the Perceptions of Psychoactive Drugs among Psychiatrists in the United States*. Poster presentation at the 84th annual conference of the College on Problems of Drug Dependence, Minneapolis, MN.
22. **Davis, A. K.**, Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Barrett, F. S., & Griffiths, R. R. (June, 2023). *Acute psychedelic effects and clinical outcomes are associated with therapeutic alliance among participants receiving psilocybin therapy*. Poster presentation accepted for the 85th annual conference of the College on Problems of Drug Dependence, Denver, CO.
23. Levin, A. W., Nagib, P., & **Davis, A. K.** (June, 2023). *Psychiatrists' persona use and social proximity to psychedelics predicts attitude towards drugs and drug users*. Poster presentation accepted for the 85th annual conference of the College on Problems of Drug Dependence, Denver, CO.
24. Lancelotta, R., Timmermann, C., Ortiz-Bernal, A., Nayak, S., Sepeda, N., Nikolaidis, A., Griffiths, R. R., & **Davis, A. K.** (June, 2023). *Associations between harm reduction strategy use and acute psychedelic effects in Spanish speakers who used LSD or Psilocybin*. Poster presentation accepted for the 85th annual conference of the College on Problems of Drug Dependence, Denver, CO.
25. Armstrong, S. B., Levin, A. W., Xin, Y., Horan, J. C., Luoma, J., Nagib, P., Pilecki, B., & **Davis, A. K.** (June, 2023). *Acceptability of psychedelic therapy differs among social workers, psychiatrists, and psychologists in the United States*. Poster presentation accepted for the 85th annual conference of the College on Problems of Drug Dependence, Denver, CO.

26. Xin, Y., Griffiths, R. R., & **Davis, A. K.** (June, 2023). *Sex differences are associated with perceived changes in baseline and post-acute religious beliefs among ayahuasca users*. Poster presentation accepted for the 85th annual conference of the College on Problems of Drug Dependence, Denver, CO.

Accepted

Unpublished Conference Posters

1. **Davis, A.K.**, Ashrafioun, L., & Osborn, L.A. (April, 2013). *Predicting sexual impulse control problems among men who have sex with men: The relationships between victimization, substance use, and internalized homonegativity*. Poster presentation at the Annual Meeting of the American Men's Studies Association, Ann Arbor, MI.
2. **Davis, A.K.**, & Rosenberg, H. (April, 2013). *Prevalence, intensity, and assessment of craving for MDMA/Ecstasy*. Poster presentation at Psychedelic Science 2013, Oakland, CA.
3. Bradbury, S., **Davis, A.K.**, Leith, J., Hinmann, N., Ashrafioun, L., Burmeister, J., & Dworsky, D. (May, 2014). *Acceptability/Morality of Verbal Harassment towards Homosexual University Students*. Midwestern Psychological Association, Chicago, IL.
4. Marx, J. M., Gonzales, S., Lackey, J.H., Bradbury, S., Zaturenskaya, M., **Davis, A.K.**, ... Froemming, M. (June, 2014). *The role of psychological flexibility in minority and non-minority students' adjustment to college*. Poster presentation at the Association of Contextual Behavioral Sciences world conference, Minneapolis, MN.
5. **Davis, A.K.** & Lauritsen, K.J. (October, 2014). *Acceptability of non-abstinence goals among students enrolled in addiction studies programs across the United States*. Poster Presentation at the Biennial Harm Reduction Coalition, Baltimore, MD.
6. Oehlhof, M., **Davis, A. K.**, Ashrafioun, L., & Osborn, L. O. (March, 2015). *Self-Objectification and Internalized Sexual Stigma Moderate Relationship between Victimization and Sexual Impulse Control among Men Who Have Sex with Men*. Poster Presentation at the inaugural International Convention of Psychological Science, Amsterdam, NL.
7. **Davis, A. K.**, Lauritsen, K. J., Lang, B., Cross, N., & Rosenberg, H. (March, 2015). *Integrating a Medical Teaching Model in a Graduate Clinical Psychology Practicum Team*. Poster Presentation at the inaugural International Convention of Psychological Science, Amsterdam, NL.
8. **Davis, A.K.**, Chermack, S., Ilgen, M., Bonar, E.E., Walton, M., Winters, J., & Blow, F. (November, 2015). *Psychiatric and Behavioral Associations of Having a Medical Marijuana Card Among Veterans in Substance Use Disorder Treatment*. Poster Presentation at The 49th Annual Convention of the Association of Cognitive and Behavioral Therapies, Chicago, IL
9. **Davis, A.K.**, Bradbury, S.L., Cross, N., Rosenberg, H., Lauritsen, K.J., Lang, B., Ashrafioun, L., ... & doek-Baik, K. (November, 2015). *Self-efficacy to Employ cognitive-behavioral strategies to reduce marijuana use among attendees at a marijuana festival in the Midwest*. Poster Presentation at The 49th Annual Convention of the Association of Cognitive and Behavioral Therapies, Chicago, IL.
10. **Davis, A.K.**, & Rosenberg, H. (November, 2015). *Using a Cognitive Behavioral Model to Predict Implementation of Harm Reduction Strategies among MDMA/ecstasy users*. Poster Presentation at The 49th Annual Convention of the Association of Cognitive and Behavioral Therapies, Chicago, IL.
11. **Davis, A.K.**, Austern, D., & Romero, E. (May, 2016). *Posttraumatic Stress Disorder treatment engagement and outcomes: Does having a co-occurring substance use disorder make a difference?* Poster presentation at the University of Maryland/VA Maryland Healthcare System Research Day, Baltimore, MD.

12. **Davis, A.K.** & Barsuglia, J. (May, 2016). *Effectiveness of Ibogaine-assisted treatment in interrupting substance use disorders: Short- and long-term outcomes and current psychological functioning*. Poster presentation at the University of Maryland/VA Maryland Healthcare System Research Day, Baltimore, MD.
13. **Davis, A.K.**, Austern, D., & Romero, E. (October, 2016). *Posttraumatic Stress Disorder treatment engagement and outcomes: Does having a co-occurring substance use disorder make a difference?* Poster presented at The 50th Annual Convention of the Association of Cognitive and Behavioral Therapies, New York City, NY.
14. **Davis, A.K.** & Barsuglia, J. (October, 2016). *Differences in treatment outcome and current cognitive and behavioral functioning of individuals who received ibogaine-assisted treatment for a substance use disorder*. Poster presented at The 50th Annual Convention of the Association of Cognitive and Behavioral Therapies, New York City, NY.
15. Bonar, E. E., Cunningham, R. M., Arterberry, B. J., **Davis, A. K.**, Collins, R. L., Blow, F. C., & Walton, M. A. (March, 2017). *Motivations for drugged driving among urban emerging adults*. Poster presented at the Collaborative Perspectives on Addiction Conference, Albuquerque, NM.
16. Barsuglia, J.P., **Davis, A.K.**, Palmer, R.S., Lancelotta, R., Windham-Harman, M., Peterson, K., Polanco, M., Grant, R.M., Griffiths, R. (April, 2017). *Characterization of Mystical Experiences Occasioned by 5-MeO-DMT-Containing Toad Venom and Comparison with Prior Psilocybin Studies*. Poster presented at Psychedelic Science 2017, Oakland, CA.
17. Malcolm, B.J., Windham-Harman, M., Lynch, M., **Davis, A.K.**, Polanco, M., Villavincencio, G.G., & Barsuglia, J.P. (April, 2017). *Changes in Withdrawal and Craving Scores in Subjects Undergoing Opioid Detoxification Utilizing Ibogaine*. Poster presented at Psychedelic Science 2017, Oakland, CA.
18. **Davis, A.K.**, Barsuglia, J.P., Polanco, M., Lynch, M., Windham-Harman, M., & Godasi, S. (April, 2017). *Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short and long-term outcomes and current psychological functioning*. Poster presented at Psychedelic Science 2017, Oakland, CA.
19. Shneeberger, D., Bonar, E. E., **Davis, A. K.**, Bourque, C., Young, S., Bauermeister, J. A., ... & Walton, M. A. (April, 2017). *Social media interventions to reduce alcohol use among youth*. Poster presentation at the Adolescent Health Initiative Conference at University of Michigan. Ann Arbor, MI.
20. Chermack, S., Winters, J., Epstein-Ngo, Q., Walton, M., Rausch, S., Bonar, E. E., **Davis, A.K.**, & Friday, S. (May, 2017). *Event-Based Analyses of Interpersonal Conflict Incidents Among Veterans in Treatment: The Role of Alcohol, Cocaine and Reasons for Conflict*. Poster Presentation at The 28th Annual Albert J. Silverman Research Conference, University of Michigan – Department of Psychiatry, Ann Arbor, MI.
21. Morris, D. H., **Davis, A.K.**, Rieth, C. M., Silvestri, M. M., Winters, J., & Chermack, S., (May, 2017). *The associations between substance use consequences, mental and behavioral health problems, and readiness to change among Veterans in seeking substance abuse treatment*. Poster Presentation at The 28th Annual Albert J. Silverman Research Conference, University of Michigan – Department of Psychiatry, Ann Arbor, MI.
22. **Davis, A.K.**, Bonar, E.E., Schneeberger, D., Bourque, C., Bohnert, A. S. B., Cunningham, R., & Walton, M., (May, 2017). *Understanding Drinking among Emerging Adults using the Dualistic Model of Passion: Associations with Alcohol Consumption, Blackouts, and Overdose*. Poster Presentation at The 28th Annual Albert J. Silverman Research Conference, University of Michigan – Department of Psychiatry, Ann Arbor, MI.
23. Chermack, S. T., Winters, J., Epstein-Ngo, Q., Walton, M. A., Friday, S., Rauch, S., Bonar, E. E., & **Davis, A. K.** (November, 2017). *Event-Based Analyses of Interpersonal Conflict Incidents Among Veterans in Treatment: The Role of Alcohol, Cocaine, and Reasons for Conflict*. Poster presented at The 51st Annual Convention of the Association of Cognitive and Behavioral Therapies, San Diego, CA.
24. Morris, D. H., **Davis, A. K.**, Reith, M., Silvestri, M. M., Winters, J., Chermack, S. T. (November, 2017). *Substance Use Consequences, Mental and Behavioral Health Problems, and Readiness to Change Among Veterans*. Poster presented at

The 51st Annual Convention of the Association of Cognitive and Behavioral Therapies, San Diego, CA.

25. **Davis, A.K.**, Barsuglia, J. P., Lancelotta, R., Grant, R., & Renn, E. (December, 2017). *5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT): Patterns of use, motives for consumption, and acute subjective effects*. The 12th Annual Bayview Research Symposium, Johns Hopkins University School of Medicine, Baltimore, MD.
26. Cox, K. E., Moshman, S. A., Barsuglia, J. P., Lancelotta, R., & **Davis, A. K.** (July, 2018). *Subjective improvements in substance use problems following 5-MeO-DMT use in an international sample*. Poster presentation at the 2018 Behavioral Pharmacology Research Unit's Poster Symposium. Baltimore, MD.
27. Sepeda, N. D., Doyle, L. Y., Clifton, J. M., Barsuglia, J. P., Lancelotta, R., Griffiths, R. R., & **Davis, A. K.** (July, 2018). *The influence of set and setting on the acute subjective effects of 5-MeO-DMT*. Poster presentation at the 2018 Behavioral Pharmacology Research Unit's Poster Symposium. Baltimore, MD.
28. Cox, K. E., Lancelotta, R., Barsuglia, J. P., & **Davis, A. K.** (November, 2018). *5-MeO-DMT is associated with subjective improvements in post-traumatic stress disorder*. Maryland Psychological Association Annual Convention 2018.
29. Armstrong, S. B. & **Davis, A. K.** (November, 2018). *Acceptability of peer support specialists in the treatment of trauma: A mixed-methods pilot study*. Poster presented at The 52nd Annual Convention of the Association of Behavioral and Cognitive Therapies, Washington, D. C.
30. So, S., Lancelotta, R., Barsuglia, J. P., Griffiths, R. R., & **Davis, A. K.** (November, 2018). *The cognitive effects of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) are associated with improvements in depression and anxiety conditions*. Poster presented at The 52nd Annual Convention of the Association of Behavioral and Cognitive Therapies, Washington, D. C.
31. Lancelotta, R., Barsuglia, J. P., & **Davis, A. K.** (November, 2018). *Using cognitive, social, and environmental benefit enhancement strategies is associated with increased positive effects of 5-MeO-DMT in recreational users*. Poster presented at The 52nd Annual Convention of the Association of Behavioral and Cognitive Therapies, Washington, D. C.
32. **Davis, A. K.**, Clifton, J. M., Hurwitz, E., & Griffiths, R. R. (December, 2018). *Examining the acute subjective and persisting effects occasioned by N,N-dimethyltryptamine (DMT): A latent class analysis*. The 13th Annual Bayview Research Symposium, Johns Hopkins University School of Medicine, Baltimore, MD.
33. **Davis, A. K.**, May, D. G., Cosimano, M., Johnson, M. W., Barrett, F. S., & Griffiths, R. R. (May, 2019). *Psilocybin-assisted psychotherapy for the treatment of Major Depressive Disorder: Preliminary results from a randomized controlled trial*. The 175th Annual Meeting of the American Psychiatric Association, San Francisco, CA.
34. **Davis, A.K.**, Arterberry, B. J., Bonar, E. E., Young, S. D., Bauermiester, J. A., Schneeberger, D., & Walton, M. A (January, 2020). *The Role of Obsessive Passion in the Experience of Negative Alcohol Use Outcomes Among Underage Risky Drinkers*. The Annual Conference of the Society for Social Work and Research, Washington, D.C.
35. Mangini, P., Xin, Y., & **Davis, A. K.** (May, 2021). *Oral ketamine-assisted psychotherapy for trauma-exposed patients in an outpatient setting: a clinical chart review study*. The 176th Annual Meeting of the American Psychiatric Association, Online.
36. Glynos, N. G., Pierce, J., **Davis, A. K.**, McAfee, J., & Boehnke, K. F. (June, 2021). *Knowledge, perceptions, and use of psychedelics among individuals with fibromyalgia*. The Annual Conference of the International Association for the Study of Pain, Online.
37. Gran-Ruiz, S., de la Salle, S., Davis, D. D., **Davis, A. K.**, Williams, M. T. (November, 2021). *Acute and enduring effects of psychedelic use among indigenous peoples on turtle island for racial trauma*. Poster presented at The 55th Annual Convention of the Association of Behavioral and Cognitive Therapies, Virtual Conference.

38. Levin, A., Nagib, P., & Davis, A.K. (May, 2022). *Perceptions of Psychoactive Drugs among Psychiatrists in the United States: The Impact of National Drug Policy*. Poster presentation accepted for the annual meeting of the American Psychiatry Association, New Orleans, LA.
39. Lopez, J., Haeny, A. M., **Davis, A. K.** & Williams, M. T. (2022, June). *Preliminary Evidence: Reduced Racial Trauma Mediates the Association between Acute Psychedelic Effects and Reduced Alcohol Use among People of Color*. Poster presented at Research Society on Alcoholism, Orlando, FL., USA.
40. Lopez, J., Haeny, A. M., **Davis, A. K.** & Williams, M. T. (2022, September). *Preliminary Evidence: Acute Psychedelic Effects Contribute to Reduced Alcohol Use, Racial Trauma, and Other Mental Health Symptoms among Latine Adults*. Poster presented at National Hispanic Science Network, Grand Rapids, MI., USA.
41. Xin, Y. & **Davis, A. K.** (November, 2022). *The acceptability of non-abstinence treatment goals among clinical social workers in the United States*. Poster presented at the 68th Annual CSWE meeting, Anaheim, CA.

Submitted

1. **Davis, A. K.** & Lancelotta, R. (January, 2024). *Naturalistic psychedelic use is associated with improvements in mental health and identity development among gender and sexual minorities*. Presentation abstract submitted to The Annual Conference of the Society for Social Work and Research, Washington, D.C.
2. **Davis, A. K.,** Armstrong, S. B., & Lancelotta, R. (January, 2024). *Developing infrastructure and methods for conducting clinical trials of psilocybin-assisted therapy*. Workshop abstract submitted to The Annual Conference of the Society for Social Work and Research, Washington, D.C.
3. Armstrong, S. B., Lancelotta, R., & Davis, A. K. (January, 2024). *Naturalistic psychedelic use and associations with unintended improvements in depression among Spanish speaking populations*. Presentation abstract submitted to The Annual Conference of the Society for Social Work and Research, Washington, D.C.
4. Xin, Y. & Davis, A. K. (January, 2024). *Changes in religious beliefs and psychospiritual outcomes following an ayahuasca retreat: A longitudinal Study*. Presentation abstract submitted to The Annual Conference of the Society for Social Work and Research, Washington, D.C.
5. Xin, Y. & Arterberry, B. J., & Davis, A. K. (January, 2024). *Passion and coping motives as predictors of alcohol use outcomes among college students who co-use cannabis and alcohol*. Presentation abstract submitted to The Annual Conference of the Society for Social Work and Research, Washington, D.C.
6. Xin, Y. & Arterberry, B. J., & Davis, A. K. (January, 2024). *Psychological flexibility mediates the relationships between passion and substance use outcomes among college students*. Presentation abstract submitted to The Annual Conference of the Society for Social Work and Research, Washington, D.C.
7. Xin, Y. & Davis, A. K. (January, 2024). *Exploring changes in substance use patterns pre- and post-ayahuasca retreat A longitudinal study design*. Presentation abstract submitted to The Annual Conference of the Society for Social Work and Research, Washington, D.C.

Oral/Podium Presentations

1. **Davis, A.K.** (November, 2012). *Acceptability of non-abstinence goals by addiction professionals in the US*. Symposium at the Biennial Harm Reduction Coalition, Portland, OR.
2. **Davis, A.K.** (November, 2012). *Confidence to reduce alcohol use and related harm*. Symposium at the Biennial Harm Reduction Coalition, Portland, OR.
3. Barsuglia, J. & **Davis, A.K.** (March, 2016). *Pre-treatment substance use patterns, differences in treatment outcome, and current psychological functioning of individuals who received ibogaine treatment for a substance use disorder*. Panel Presentation at the Global Ibogaine Therapy Alliance International Conference, Tepotzlan, MX.

4. **Davis, A. K., & Lancelotta, R.** (April, 2018). *The healing potential of 5-MeO-DMT: Results from two survey studies*. Oral presentation at the Midwest Psychedelic Therapy Symposium, Madison, WI.
5. **Davis, A. K.** (April, 2019). *Psychological flexibility and motivation to change substance use following a psychedelic experience in naturalistic settings*. Oral presentation as part of a symposium at the Collaborative Perspectives on Addiction conference, Providence, RI.
6. **Davis, A. K.** (June, 2019). *Psilocybin-assisted psychotherapy for the treatment of Major Depressive Disorder: Preliminary results from a randomized controlled trial*. Oral presentation at the Annual Johns Hopkins University Department of Psychiatry Research Potpourri, Baltimore, MD.
7. **Davis, A. K.** (January, 2020). *Psychological Flexibility Mediates the Relationship Between Co-occurring Stress and Mental Health Problems and Academic Performance among Undergraduate College Students*. The Annual Conference of the Society for Social Work and Research, Washington, D.C.
8. **Davis, A. K.** (September, 2020). *Psychedelics contribute to decreases in mental health symptoms among people of color who have a history of racial trauma*. The Interdisciplinary Conference of Psychedelic Research, Haarlem, Netherlands (Online Conference).
9. **Davis, A. K.** (January, 2021). *Increases in psychological flexibility mediate the relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color*. The Annual Conference of the Society for Social Work and Research, Virtual.
10. **Davis, A. K., Brooke J. Arterberry, Shane W. Kraus** (March, 2021). *Exploring a new construct for substance use and addictive behaviors: The dualistic model of passion*. Oral presentation as part of a symposium at the Collaborative Perspectives on Addiction conference, Virtual Conference.
27. **Davis, A.K.** (June, 2021). *Self-reported increases in cannabis use during the COVID-19 pandemic associated with cannabis use disorder (CUD) symptoms, consequences, and amphetamine misuse among college student with CUD*. Oral presentation at the 83rd annual conference of the College on Problems of Drug Dependence, Virtual.
28. **Davis, A.K., Xin, Y., Lancelotta, R., & Clifton, J.** (January, 2022). *Attitudes about and experiences with psychedelic drug use among Black, Indigenous, and People of Color populations*. Symposium presented at the annual conference of the Society for Social Work and Research, Washington, DC.
29. **Davis, A.K.** (January, 2022). *Self-reported increases in cannabis use during the COVID-19 pandemic associated with cannabis use disorder (CUD) symptoms, consequences, and amphetamine misuse among college students with CUD*. Presentation as part of symposium presented at the annual conference of the Society for Social Work and Research, Washington, DC.
30. **Armstrong, S. B., Xin, Y., Sepeda, N.S., Averill, L.A., & Davis, A.K.** (June, 2022). *Prospective associations of psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans*. Oral presentation at the 84th annual conference of the College on Problems of Drug Dependence, Minneapolis, MN.
31. **Davis, A.K., Sepeda, N. S., Xin, Y., & Armstrong, S. B.** (January, 2023). *Psychedelic therapy for United States military Veterans with a history of combat and deployment trauma*. Symposium presented at the annual conference of the Society for Social Work and Research, Phoenix, AZ.
32. **Davis, A. K., Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Barrett, F. S., Griffiths, R. R.** (April, 2023). *Therapeutic alliance in psilocybin-assisted therapy: Associations with acute psychedelic effects and clinical outcomes*. Oral presentation at Breaking Convention, The University of Exeter in Exeter, UK.

33. **Davis, A. K.**, Sevelius, J., Quinn, D., Ching, T., Adusei, K., Lancelotta, R., Estrada, Y. (June, 2023). *Increasing safety and participation in psychedelic science and communities among people of the global majority and gender/sexually expansive people*. Panel presentation accepted for Psychedelic Science 2023, Denver, CO.

Accepted

Service & Philanthropic Activities

- 2017 – Present President/Founding Director, Board of Directors
Source Research Foundation
- 2019 – Present Faculty Advisor, MSW Program
College of Social Work
The Ohio State University
- 2019 – Present Reviewer, PhD Program Applications
College of Social Work
The Ohio State University
- 2019 – Present Faculty Advisor, BSSW Program
College of Social Work
The Ohio State University
- 2019 – 2022 Member, Interdisciplinary Trauma Certificate Program Development Working Group
College of Social Work
The Ohio State University
- 2019 – 2023 Faculty Advisor, The Psychedelics Association
The Ohio State University
- 2019 – 2020 Member, Substance Use Curriculum Review Group
College of Social Work
The Ohio State University
- 2020 – 2020 Member, Ad-hoc Teaching and Learning Committee
College of Social Work
The Ohio State University
- 2020 – 2020 Member, Field Placement Award Committee
College of Social Work
The Ohio State University
- 2020 – 2020 Judge/Reviewer, Edward F Hayes Graduate Research Forum
The Ohio State University
- 2020 – 2022 Faculty Advisor, Consciousness Interests Research Group
College of Medicine
The Ohio State University
- 2020 – 2022 Member, Advisory Committee
University of Toronto and Canada Mental Health Chair
Conference planning
- 2020 – 2022 Member-at-large, Board of Directors
The Columbus Gay Men's Chorus

- 2020 – 2022 Member, Board of Advisors
Intercollegiate Psychedelics Network
- 2020 – 2022 Faculty Member, BSSW Committee
College of Social Work
The Ohio State University
- 2020 – 2022 Reviewer, President’s postdoctoral award
Office of Postdoctoral Affairs
The Ohio State University
- 2020 – Present Chair, SSWR Addiction Special Interest Group
Society of Social Work and Research
- 2021 – Present Member, Student Wellness Committee
Office of Military and Veteran Services
The Ohio State University
- 2021 – 2022 Member, Advisory Board
Apollo Pact, Inc.
- 2021 – 2023 Faculty Member, MSW Committee
College of Social Work
The Ohio State University
- 2021– 2023 Faculty Member, Research Advisory Committee
College of Social Work
The Ohio State University
- 2022 – 2022 Consultant (unpaid), Drug Content Moderator Team
Meta (Facebook)
- 2022 – Present Member, Travel Awards Committee
College on Problems of Drug Dependence
- 2023 – Present Faculty Senator for the College of Social Work
The Ohio State University